Universal cervical length screening and vaginal progesterone: Distinguishing strategy effectiveness from treatment efficacy
Mira Zethelius, Lina Bergman, Ann‐Catrin Ekelund, Cecilie Hongslo Vala, Bo Jacobsson, Pihla Kuusela, Ann Liljegren, Björn Lindkvist, Max Petzold, Petteri Sjögren, Ulla‐Britt Wennerholm, Tove Wikström · 2026
Read Universal cervical length screening and vaginal progesterone: Distinguishing strategy effectiveness from treatment efficacy by Mira Zethelius, Lina Bergman, Ann‐Catrin Ekelund, Cecilie Hongslo Vala, Bo Jacobsson, Pihla Kuusela, Ann Liljegren, Björn Lindkvist, Max Petzold, Petteri Sjögren, Ulla‐Britt Wennerholm, Tove Wikström (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13530915.txt.
Description
Mira Zethelius and co-authors reply to critics of their screening review in a 2026 letter. The review asked if checking every pregnant woman cervix length, then giving progesterone to those with a short cervix, lifts outcomes for the whole group. Critics had pressed on what the trials inside could prove.
The authors agree the two trials were built to test the strategy, not the drug worth in short cervix cases. They also grant the trials had low power, which their grade of proof marked as very low. Their claim stands narrow: the strategy value stays unsure, and bigger trials are needed before firm guidance.
Catalog record
| CREATOR | Mira Zethelius, Lina Bergman, Ann‐Catrin Ekelund, Cecilie Hongslo Vala, Bo Jacobsson, Pihla Kuusela, Ann Liljegren, Björn Lindkvist, Max Petzold, Petteri Sjögren, Ulla‐Britt Wennerholm, Tove Wikström |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 4 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |